If an adrenal adenoma appears larger, should I repeat the CT scan in three months or six months to assess growth?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Repeat CT in 6 Months for Growing Adrenal Adenomas

For an adrenal adenoma that appears larger on follow-up imaging, repeat CT scanning should be performed in 6 months, not 3 months, based on current guideline recommendations. 1

Algorithmic Approach to Follow-Up Timing

The 2023 CUA/AUA guidelines provide clear direction on this scenario:

For Radiologically Benign Lesions ≥4 cm:

  • Repeat imaging at 6-12 months if the lesion is radiologically benign (<10 HU on non-contrast CT) but measures ≥4 cm 1
  • The 6-month interval represents the earliest appropriate timeframe for reassessment

For Indeterminate Non-Functional Lesions:

  • Repeat imaging at 3-6 months is recommended when shared decision-making favors surveillance over surgical resection 1
  • The 3-month option applies specifically to indeterminate lesions where there's higher concern for malignancy

Growth Rate Thresholds That Matter:

Once you obtain follow-up imaging, the growth pattern determines next steps:

  • >5 mm/year growth: Consider adrenalectomy after repeating functional workup 1
  • <3 mm/year growth: No further imaging or functional testing required 1
  • Growth of ≥8 mm in 12 months: Warrants further investigation 2

Clinical Context and Reasoning

The 6-month interval for confirmed adenomas (rather than 3 months) is based on the natural history of adrenal lesions. Recent data shows that 95% of benign nodules grow between -2 to +2 mm annually 3. Malignant lesions, in contrast, grow at an order of magnitude faster—the single malignant nodule in one cohort grew 13 mm in just 39 days 3. This stark difference means:

  • If truly malignant: Even a 6-month delay won't miss a clinically significant cancer, as it will demonstrate obvious rapid growth
  • If benign: The 6-month interval avoids unnecessary radiation exposure and healthcare costs from overly frequent imaging

Important Caveats

Always repeat functional workup if the lesion is growing, even if initially non-functional. Some hormonally active lesions (like pheochromocytomas) can remain stable in size yet still be dangerous 2.

The 3-month option is reserved for truly indeterminate lesions—those with attenuation >10 HU on non-contrast CT or other concerning features that couldn't be definitively characterized as benign 1. If your adenoma was confirmed as benign initially (HU <10), the 6-month timeframe applies.

Size matters for initial surveillance decisions: Benign non-functional adenomas <4 cm require no follow-up imaging at all 1. The fact that you're considering repeat imaging suggests this lesion is either ≥4 cm or has indeterminate features.

References

Guideline

imaging of adrenal masses.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Research

Incidental Adrenal Nodules and Growth Rates: A Single Centre Retrospective Cohort Study.

Journal of medical imaging and radiation oncology, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.